What we do 3B Blackbio DX Ltd is a leading Indian biotech company specializing in molecular diagnostics, agrochemicals, and rapid diagnostic tests for infectious diseases and cancer. |
Founded in 1,972 |
Market share Holds 12-15% market share in Indian molecular diagnostics; recognized among market leaders with worldwide presence in 70+ countries. |
Problem solved Provides advanced diagnostics solutions for cancer, infectious diseases and antimicrobial resistance, supporting early detection and personalized treatment. |
Top clients or who we serve Serves labs, hospitals, government sectors, including Indian armed forces, food and health agencies; B2B primarily. |
Key management Dhirendra Dubey (Chairman & Managing Director) with over 30 years of biotech and diagnostics experience leading R&D and growth. |
Our journey and innovations Incorporated in 1972; shifted from agrochemicals to biotech diagnostics; launched India’s first FDA EUA PCR kit; acquired Coris BioConcept Belgium. |
Where we operate India, UK, Europe, Middle East, APAC, LATAM, North America; expanding into Africa. |
Top products or what we offer Molecular diagnostic kits (TRUPCR®), Next-Gen Sequencing assays (TRUNGS®), Rapid tests (TRURAPID®), agrochemicals, and bio-products. |
Top brands TRUPCR® (PCR kits) - #1 Indian molecular diagnostics brand; TRURAPID® (rapid tests); TRUNGS® (NGS assays); Coris BioConcept rapid diagnostics. |
Raw materials needed Specialized reagents, enzymes, chemicals for molecular diagnostics and agrochemical formulations. |
Raw materials supplier Not specifically disclosed; sourced globally with stringent quality controls. |
Recurring vs cyclical contribution Diagnostics segment shows recurring revenue via contracts and reagent rentals; agrochemicals more cyclical with government tenders. |
Our industry position Among India’s largest molecular diagnostics firms; strong global footprint; integrated PCR, rapid tests, and NGS solutions provider. |
Financial highlights FY 2024-25 consolidated revenue approx. Rs. 96.47 Cr; net profit Rs. 47.69 Cr; sustained ~29% CAGR in diagnostics business. |
Geographical revenue split Major revenue from India and international markets including Europe, Middle East, APAC, LATAM, North America. |
Order book - |
Whats driving growth Rising demand for molecular diagnostics in infectious diseases and oncology, government initiatives, strategic exports, R&D innovation, and acquisitions. |
Our future plans Expand rapid test portfolio, strengthen regulatory compliance (IVDR), scale international presence, and enhance digital PCR and automated extraction technologies. |
Our green promise Committed to sustainable manufacturing and green initiatives, minimizing environmental impact though specific actions not detailed. |
Our people and values Strong R&D team with PhDs and experienced scientists; culture focused on innovation, quality, and social responsibility; CSR initiatives active. |
Key challenges ahead Intense competition, regulatory complexities, geopolitical tensions affecting exports, and market penetration in emerging geographies. |
Interesting facts First Indian molecular diagnostics company to get US FDA EUA for COVID PCR; owns a global monopoly rapid test for African sleeping sickness. |
Risks and strategy Mitigate regulatory and market risks through quality certifications, diversified product range, strategic partnerships, and continued acquisitions. |
